Canary is Developing Three Classes of Tests

Our tests will include DNA only, RNA only or DNA+RNA

Lab Test Comparisons

Test Result Canary Oncoceutics Canary Acuity Canary Oncoceutics Canary Lumina Company A Company B Company C Company D Company E
# of Genes Analyzed via NGS 1091 (+637 Variants) DNA + RNA 302 341 517 523 648
Therapeutic SNVs and INDELS
Amplifications and Deletions
Fusions genes
Tumor Mutational Burden (TMB)
Microsatellite Instability (MSI)
TCR Clonality
Homologous Recombination Deficiency (HRD)
Loss of Heterozygosity (LOH)
Comprehensive proprietary database of FDA approved/clinical trial drugs for corresponding biomarkers
Depiction of cancer-relevant pathways
Germline variants affecting drug metabolism
Complete ACMG Oncology Germline Mutational Analysis
ImmunoInsightTM score (Tumor Immunogenicity)
Tumor Lymphoid Structures Levels (TLS)
Tumor Infiltrating Lymphocytes (TILs)
Therapeutic Response Prediction
Overall Survival Prediction

Tests where Canary has a differentiated advantage

Canary’s Test Provides a Powerful Clinical Advantage

Example of Canary AcuityTM Benefits in Immunotherapy Testing

Canary AcuityTM Company A
Tumor Mutation Burden (1091 genes)” Tumor Mutation Burden (324 genes)
Microsatellite Instability (1091 genes + 51 markers) Microsatellite Instability (324 genes)
TCR Clonality (110 genes) N/A

The more genes sequenced, the more accurate the immunotherapy biomarker predictions

Get In Touch

Address

20 E Thomas Road, Suite 2203, Phoenix, Arizona, 85012, USA

Phone

1-888-909-9809

loader